Bristol-Myers Squibb Company (BMY) Presents at Morgan Stanley 23rd Annual Global

Terence Flynn
Equity Analyst

All right. Thanks. I think we’re going to get started. But I’m Terence Flynn, Morgan Stanley’s U.S. biopharma analyst. I’m very pleased to be hosting Bristol-Myers this morning. Joining us from the company, we have Chris Boerner, the company’s CEO; and Adam Lenkowsky, the company’s Chief Commercial Officer.

For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

With that, I’m going to turn it over to Chris for some opening remarks, and then we’re going to go into Q&A. But thanks so much both for being with us today. Really appreciate the time.

Christopher Boerner
CEO & Chairman

Thank you. It’s great to be here. And maybe just a quick update. I think the market is pretty familiar with the LOE exposure that we have with the company. So maybe I’ll just give you a sense of where we are now almost 2 years into the journey that we’re on as a company. Broadly defined, we’re working against a strategy that has sort of 3 big components to it.

First, we’ve got to deliver on the products that we have on the market that are going to drive the growth of the company as we get to the back end of the decade. And Adam obviously can speak to more details around it. But I think if you look quarter-over-quarter, we’ve seen consistent performance coming out of the commercial organization. Most recently, we showed very good growth in the